LakeShore Biopharma Co., Ltd (LSB)
NASDAQ: LSB · Real-Time Price · USD
0.745
-0.035 (-4.49%)
Sep 19, 2024, 4:00 PM EDT - Market closed
LakeShore Biopharma Income Statement
Financials in millions CNY. Fiscal year is April - March.
Millions CNY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 573.42 | 573.42 | 687.2 | 502.95 | 257.02 |
| Revenue Growth (YoY) | -16.56% | -16.56% | 36.63% | 95.69% | - |
| Cost of Revenue | 187.36 | 187.36 | 153.36 | 121.46 | 59.66 |
| Gross Profit | 386.06 | 386.06 | 533.84 | 381.49 | 197.36 |
| Selling, General & Admin | 434.56 | 434.56 | 339.33 | 278.76 | 224.82 |
| Research & Development | 302.8 | 302.8 | 318.7 | 211.22 | 94.39 |
| Other Operating Expenses | 6.79 | 6.79 | 6.54 | 5.38 | 4 |
| Operating Expenses | 744.15 | 744.15 | 664.57 | 495.37 | 323.21 |
| Operating Income | -358.09 | -358.09 | -130.73 | -113.88 | -125.85 |
| Interest Expense | -44.34 | -44.34 | -30.86 | -2.72 | -29.69 |
| Other Non Operating Income (Expenses) | 27.48 | 27.48 | 17.24 | 15.53 | -18.83 |
| EBT Excluding Unusual Items | -374.96 | -374.96 | -144.35 | -101.07 | -174.37 |
| Gain (Loss) on Sale of Investments | - | - | -137.99 | -130.66 | -16.61 |
| Asset Writedown | -80.24 | -80.24 | - | - | - |
| Pretax Income | -455.19 | -455.19 | -282.34 | -231.73 | -190.98 |
| Income Tax Expense | -21.73 | -21.73 | 1.13 | 4.94 | 17.45 |
| Net Income | -433.46 | -433.46 | -283.47 | -236.67 | -208.44 |
| Preferred Dividends & Other Adjustments | - | - | -137.99 | -130.66 | -16.61 |
| Net Income to Common | -433.46 | -433.46 | -145.48 | -106 | -191.83 |
| Shares Outstanding (Basic) | 107 | 107 | 62 | 62 | 62 |
| Shares Outstanding (Diluted) | 107 | 107 | 62 | 62 | 62 |
| Shares Change (YoY) | 73.06% | 73.06% | -0.07% | - | - |
| EPS (Basic) | -4.05 | -4.05 | -2.35 | -1.71 | -3.10 |
| EPS (Diluted) | -4.05 | -4.05 | -2.35 | -1.71 | -3.10 |
| Free Cash Flow | -339.48 | -339.48 | -235.23 | -468.86 | -351.49 |
| Free Cash Flow Per Share | -3.17 | -3.17 | -3.81 | -7.58 | -5.69 |
| Gross Margin | 67.33% | 67.33% | 77.68% | 75.85% | 76.79% |
| Operating Margin | -62.45% | -62.45% | -19.02% | -22.64% | -48.96% |
| Profit Margin | -75.59% | -75.59% | -21.17% | -21.08% | -74.64% |
| Free Cash Flow Margin | -59.20% | -59.20% | -34.23% | -93.22% | -136.76% |
| EBITDA | -315.9 | -315.9 | -94.04 | -82.72 | -97.94 |
| EBITDA Margin | -55.09% | -55.09% | -13.68% | -16.45% | -38.11% |
| D&A For EBITDA | 42.19 | 42.19 | 36.69 | 31.15 | 27.91 |
| EBIT | -358.09 | -358.09 | -130.73 | -113.88 | -125.85 |
| EBIT Margin | -62.45% | -62.45% | -19.02% | -22.64% | -48.96% |
Source: S&P Capital IQ. Standard template. Financial Sources.